Palestinian Medical and Pharmaceutical Journal (Pal. Med. Pharm. J.)

Role of Dapagliflozin versus Empagliflozin as add-on Therapy on Diabetic Nephropathy

Article info

2024-10-22
2025-02-20
2025-02-23
None - None

Keywords

  • Diabetic Nephropathy
  • Albuminuria
  • Empagliflozin
  • glomerular filtration rate
  • Dapagliflozin

Abstract

Background: Diabetic nephropathy affect approximately 50% of type 2 diabetics. Early detection of kidney disease is crucial to reduce deterioration of renal function, beside reversing microalbuminuria showed beneficial effects in delaying the onset or even reversing the progression of the disease. Recently, sodium/glucose cotransporter-2 inhibitors have received attention for their anti-inflammatory and reno-cardioprotective effects. Aim: This interventional study aimed to evaluate and compare the clinical outcomes of two sodium/glucose cotransporter-2 inhibitors, Dapagliflozin vs. Empagliflozin, as add-on therapy on renal function parameters and other injury markers. Methodology: Forty-one of type 2 diabetic nephropathy patients had been divided into two groups randomly. The first group treated with Dapagliflozin 5mg/day and the second group treated with Empagliflozin 10 mg/day, for 16 weeks as add-on. Blood and urine samples were collected at baseline and at week 16 to evaluate the glycemic, weight parameters, renal function (urinary albumin/creatinine ratio, serum urea and creatinine, estimated glomerular filtration rate, and lipid profile. Results: After 16 weeks, Dapagliflozin and Empagliflozin significantly reduced HbA1c, body mass index, waist circumference (p<0.01). Albuminuria reduced significantly with Empagliflozin and Dapagliflozin (p<0.05). A mild elevation in serum creatinine was observed with significant difference between two medications. Empagliflozin showed a mild reduction in glomerular filtration rate compared with Dapagliflozin. Empagliflozin significantly reduced cholesterol while Dapagliflozin significantly reduced LDL-c, TG and VLDL levels (p<0.05). No change in HDL-c level in both groups. Conclusion: Adding Dapagliflozin or Empagliflozin effectively improved albuminuria, glycemic status and weight parameters. The preference was for Dapagliflozin regarding renal function and lipids.

Role of Dapagliflozin versus Empagliflozin as add-on Therapy on Diabetic Nephropathy

معلومات المقال

2024-10-22
2025-02-20
2025-02-23
None - None

الكلمات الإفتتاحية

  • Diabetic Nephropathy
  • Albuminuria
  • Empagliflozin
  • glomerular filtration rate
  • Dapagliflozin

الملخص

Background: Diabetic nephropathy affect approximately 50% of type 2 diabetics. Early detection of kidney disease is crucial to reduce deterioration of renal function, beside reversing microalbuminuria showed beneficial effects in delaying the onset or even reversing the progression of the disease. Recently, sodium/glucose cotransporter-2 inhibitors have received attention for their anti-inflammatory and reno-cardioprotective effects. Aim: This interventional study aimed to evaluate and compare the clinical outcomes of two sodium/glucose cotransporter-2 inhibitors, Dapagliflozin vs. Empagliflozin, as add-on therapy on renal function parameters and other injury markers. Methodology: Forty-one of type 2 diabetic nephropathy patients had been divided into two groups randomly. The first group treated with Dapagliflozin 5mg/day and the second group treated with Empagliflozin 10 mg/day, for 16 weeks as add-on. Blood and urine samples were collected at baseline and at week 16 to evaluate the glycemic, weight parameters, renal function (urinary albumin/creatinine ratio, serum urea and creatinine, estimated glomerular filtration rate, and lipid profile. Results: After 16 weeks, Dapagliflozin and Empagliflozin significantly reduced HbA1c, body mass index, waist circumference (p<0.01). Albuminuria reduced significantly with Empagliflozin and Dapagliflozin (p<0.05). A mild elevation in serum creatinine was observed with significant difference between two medications. Empagliflozin showed a mild reduction in glomerular filtration rate compared with Dapagliflozin. Empagliflozin significantly reduced cholesterol while Dapagliflozin significantly reduced LDL-c, TG and VLDL levels (p<0.05). No change in HDL-c level in both groups. Conclusion: Adding Dapagliflozin or Empagliflozin effectively improved albuminuria, glycemic status and weight parameters. The preference was for Dapagliflozin regarding renal function and lipids.

Since 2022

Cite Score (Scopus): 0.8
Time to First Decision: 3 Days
Submission to Acceptance: 45 Days
Acceptance Rate: 17%
Why should you
Publish With Us?
An-Najah National University
Nablus, Palestine
P.O. Box
7, 707
Fax
(970)(9)2345982
Tel.
(970)(9)2345560
(970)(9)2345113/5/6/7-Ext. 2628
E-mail
[email protected]
EIC
Prof. Waleed Sweileh

The Palestinian Medical and Pharmaceutical Journal (Pal. Med. Pharm. J.) © 2024 by An-Najah University, Nablus, Palestine is licensed under CC BY-NC 4.0

News and Views